Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01647633 · ClinicalTrials.gov registry record · Phase 1
Effects of AkPharma's Calcium Glycerophosphate Nasal Spray Wash
A Phase 1 study of Allergic Rhinitis, sponsored by Drexel University.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT01647633 is a Phase 1 study of Allergic Rhinitis that has completed, run by Drexel University. The registered enrollment target is 17 participants, below the 105-participant average among 23 other Allergic Rhinitis trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01647633, a Phase 1 study of Allergic Rhinitis, has completed, sponsored by Drexel University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
Over 20 million Americans have allergic nasal symptoms including stuffiness, sneezing and a "runny" nose. AkPharma's Calcium Glycerophosphate used as a nasal spray wash is believed to improve these symptoms without side effects common to over the counter and prescription medication. It is hypothesized that Calcium Glycerophosphate will have a perceived improvement in breathing comfort.
Conditions Studied
Interventions
- OTHER Calcium Glycerophosphate Nasal Spray Wash
Study Locations (1)
Pennsylvania
- Drexel University College of Medicine - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2012-05 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01647633
The ClinicalTrials.gov registry entry for NCT01647633 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 105-participant average among 23 other Allergic Rhinitis trials with a reported enrollment target (84% lower). The listed sponsor is Drexel University, which has 92 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allergic Rhinitis appearing as the primary indexed condition, and to 1 intervention - of which Calcium Glycerophosphate Nasal Spray Wash is the first listed.
NCT01647633 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01647633 about?
NCT01647633 is a clinical study titled "Effects of AkPharma's Calcium Glycerophosphate Nasal Spray Wash". Over 20 million Americans have allergic nasal symptoms including stuffiness, sneezing and a "runny" nose. AkPharma's Calcium Glycerophosphate used as a nasal spray wash is believed to improve these symptoms without side effects common to over the counter and prescription medication. It is hypothesiz...
What is the current status of trial NCT01647633?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2012-05. Estimated completion is 2015-05.
What conditions does trial NCT01647633 study?
This clinical trial studies the following conditions: Allergic Rhinitis.
What interventions are being tested in trial NCT01647633?
The interventions under investigation include: Calcium Glycerophosphate Nasal Spray Wash (OTHER).
Who is sponsoring clinical trial NCT01647633?
This trial is sponsored by Drexel University, which has 92 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01647633 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Rhinitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Safety and Immunogenicity Phase IC Study of CryJ2 -DNA-LAMP Plasmid Vaccine for Assessment of Intradermal (ID) Route of Administration Using the Biojector 2000 Device
COMPLETED · Phase 1
-
Does Batten Grafting Improve Nasal Outcomes in Septoplasty and Turbinate Reduction?
RECRUITING · NA
-
Viral Mucosal Reprogramming
RECRUITING · Phase 2
-
Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease
ACTIVE NOT RECRUITING · Phase 4
-
Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis
COMPLETED · Phase 3
-
Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.